Variant: rs121913369 

    present in Gene: BRAF
    present in Chromosome: 7
    Position on Chromosome: 140753346
    Alleles of this Variant: G/A;C

rs121913369 in BRAF gene and Carcinoma of lung PMID 12460918 2002 BRAF and RAS mutations in human lung cancer and melanoma.

PMID 22798288 2012 BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.

PMID 23833300 2013 Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.

PMID 12460919 2002 Missense mutations of the BRAF gene in human lung adenocarcinoma.

PMID 22649091 2012 Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.

PMID 19010912 2008 Genetic predictors of MEK dependence in non-small cell lung cancer.

PMID 19238210 2009 Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.

PMID 12068308 2002 Mutations of the BRAF gene in human cancer.

PMID 21483012 2011 Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.

rs121913369 in BRAF gene and Cardio-facio-cutaneous syndrome PMID 15035987 2004 Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

PMID 23093928 2012 A structural systems biology approach for quantifying the systemic consequences of missense mutations in proteins.

PMID 19206169 2009 Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.

PMID 22892241 2012 The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.

rs121913369 in BRAF gene and NOONAN SYNDROME 7 PMID 19206169 2009 Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.

PMID 20876176 2010 Noonan syndrome: clinical features, diagnosis, and management guidelines.

rs121913369 in BRAF gene and Neoplasms PMID 15035987 2004 Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

rs121913369 in BRAF gene and Non-Small Cell Lung Carcinoma PMID 15035987 2004 Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

PMID 23093928 2012 A structural systems biology approach for quantifying the systemic consequences of missense mutations in proteins.

PMID 19206169 2009 Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.

PMID 22892241 2012 The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.

rs121913369 in BRAF gene and Noonan Syndrome PMID 23093928 2012 A structural systems biology approach for quantifying the systemic consequences of missense mutations in proteins.

PMID 22892241 2012 The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.

PMID 19206169 2009 Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.

PMID 15035987 2004 Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

rs121913369 in BRAF gene and melanoma PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

PMID 23833300 2013 Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.

PMID 22805292 2012 Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

PMID 23715574 2013 Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.

PMID 21483012 2011 Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.

PMID 19238210 2009 Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.

PMID 22649091 2012 Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.

PMID 12068308 2002 Mutations of the BRAF gene in human cancer.

PMID 12460918 2002 BRAF and RAS mutations in human lung cancer and melanoma.

PMID 19010912 2008 Genetic predictors of MEK dependence in non-small cell lung cancer.

PMID 12460919 2002 Missense mutations of the BRAF gene in human lung adenocarcinoma.

PMID 22798288 2012 BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.